MediWound Ltd. (NASDAQ:MDWD) tinted gains of +0.94% (+0.04 points) to US$4.29. The volume of 0.14 Million shares climbed down over an trading activity of 36.81 Million shares. EPS ratio determined by looking at last 12 month figures is -0.51. Over the same time span, the stock marked US$7.35 as its best level and the lowest price reached was US$3.56. The corporation has a market cap of US$113.68 Million.
MediWound Ltd. (NASDAQ:MDWD)’s earnings per share has been growing at a -23.7 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -403.7 percent while most common profitability ratio return on investment (ROI) was -142.6 percent. The company’s institutional ownership is monitored at 36.8 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 38.3 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 3 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.4. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Digital Ally, Inc. (NASDAQ:DGLY) is worth US$29.89 Million and has recently fallen 0% to US$2.91. The latest exchange of 0.06 Million shares is below its average trading activity of 79.08 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$4.95 while the mean 12-month price target for the shares is US$5.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 6.77, and a price to sales ratio of 2.53. For the past 5 years, the company’s revenue has grown -3.7%, while the company’s earnings per share has grown -24.5%. With an institutional ownership near 3.9%, it carries an earnings per share ratio of -2.59.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.